molecularly targeted agents into the treatment of…
““molecularly targeted agents into the treatment of early-stage NSCLC. At this time, however, such an approach cannot be recommended outside a clinical trial. In the NCI-C JBR.19 trial, which was terminated early when gefitinib lost its U.S. Food and Drug Administration (FDA) approval, administration of the EGFR inhibitor gefitinib after resection of stage I to III NSCLC did not improve OS. Surprisingly, a subset analysis of patients with tumors harboring activating EGFR mutations, a population expected to derive particular benefit from such an approach, suggested the possibility of a detrimental effect from gefitinib. Similarly, the use of antiangiogenic agents and ALK inhibitors after surgery for advanced disease remains investigational.””
About This Quote
This interpretation was drafted with AI assistance. It is one reading of the quote, not the author's own explanation.
Current evidence does not support using targeted therapies after early-stage lung cancer surgery outside trials; potential harm exists for certain mutations.
In simple terms: Targeted drugs aren’t recommended post‑surgery except in studies.
Key Takeaway
Follow evidence‑based guidelines and enroll in trials when appropriate.
Themes
oncology
clinical research
patient safety
Mood
cautious
analytical
Type
clinical
informative
When to use this quote
- treatment planning
- patient counseling
- clinical trial enrollment
- policy making
Key Concepts
evidence hierarchy
personalized medicine
Questions to Reflect On
- What factors would justify broader use?
- How can patients stay informed about evolving therapies?
A Different Perspective
Results may change with new data; limited to specific trial context.